Everything below concerns BPC-157. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Dry powder storage | -20 °C or below | Desiccated and protected from light |
| Solution storage | 2-8 °C, short term | Aliquot to avoid freeze-thaw cycling |
| Reconstitution solvent | Water or buffered saline | Near-neutral pH is generally preferred |
| Identity confirmation | Mass spectrometry | Matches expected monoisotopic mass |
| Purity assessment | Reverse-phase HPLC | Reported as main-peak area percentage |
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
== History == Pioneered by Stanley Fields and Ok-Kyu Song in 1989, the technique was originally designed to detect protein–protein interactions using the Gal4 transcriptional activator of the yeast Saccharomyces cerevisiae. The Gal4 protein activated transcription of a gene involved in galactose utilization, which formed the basis of selection. Since then, the same principle has been adapted to describe many alternative methods, including some that detect protein–DNA interactions or DNA-DNA interactions, as well as methods that use different host organisms such as Escherichia coli or mammalian cells instead of yeast.
In the US, Aducanumab is indicated for the treatment of Alzheimer's disease. In July 2021, the US Food and Drug Administration (FDA) limited the indication to people with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Aducanumab is a monoclonal IgG1 antibody that binds to the amyloid beta protein at amino acids 3–7, which is posited to result in slowing the progression of Alzheimer's disease. The mechanism is based on the amyloid hypothesis, which posits that amyloid proteins cause Alzheimer's disease, hence removing amyloid should slow the progression of the disease. How the antibody accesses the plaques is under active research. One mechanism suggests the plaques are exposed to the lumen of blood vessels and the antibody accesses the plaques from the lumen side. This assumes the plaque formed as a result of a leaky blood brain barrier and may also explain why there is hemorrhage after the plaques are removed. The most common serious adverse reactions reported are:
In a DNA double helix, each type of nucleobase on one strand bonds with just one type of nucleobase on the other strand. This is called complementary base pairing. Purines form hydrogen bonds to pyrimidines, with adenine bonding only to thymine in two hydrogen bonds, and cytosine bonding only to guanine in three hydrogen bonds. This arrangement of two nucleotides binding together across the double helix (from six-carbon ring to six-carbon ring) is called a Watson-Crick base pair. DNA with high GC-content is more stable than DNA with low GC-content. A Hoogsteen base pair (hydrogen bonding the 6-carbon ring to the 5-carbon ring) is a rare variation of base-pairing. As hydrogen bonds are not covalent, they can be broken and rejoined relatively easily. The two strands of DNA in a double helix can thus be pulled apart like a zipper, either by a mechanical force or high temperature. As a result of this base pair complementarity, all the information in the double-stranded sequence of a DNA helix is duplicated on each strand, which is vital in DNA replication. This reversible and specific interaction between complementary base pairs is critical for all the functions of DNA in organisms.
Although hydroperoxide often refers to a class of organic compounds, many inorganic or metallo-organic compounds are hydroperoxides. One example involves sodium perborate, a commercially important bleaching agent with the formula Na2[(HO)2B]2(OO)2)]. It acts by hydrolysis to give a boron-hydroperoxide: [(HO)2B]2(OO)2)2− + 2 H2O ⇌ 2 [(HO)3B(OOH)]− This hydrogen peroxide then releases hydrogen peroxide: [(HO)3B(OOH)]− + H2O ⇌ B(OH)−4 + H2O2 Several metal hydroperoxide complexes have been characterized by X-ray crystallography, for example: triphenylsilicon and triphenylgermanium hydroperoxides can be obtained by reaction of initial chlorides with excess of hydrogen peroxide in presence of base. Some form by the reaction of metal hydrides with oxygen gas: LnM−H + O2 → LnM−O−O−H (Ln refers to other ligands bound to the metal) Some transition metal dioxygen complexes abstract H atoms (and sometimes protons) to give hydroperoxides: LnM(O2) + H → LnMOOH
Benzodiazepines are positive allosteric modulators of the GABA type A receptors (GABAA). The GABAA receptors are ligand-gated chloride-selective ion channels that are activated by GABA, the major inhibitory neurotransmitter in the brain. The binding of benzodiazepines to this receptor complex promotes the binding of GABA, which in turn increases the total conduction of chloride ions across the neuronal cell membrane. This increased chloride ion influx hyperpolarizes the neuron's membrane potential. As a result, the difference between resting potential and threshold potential is increased, and firing is less likely. As a result, the arousal of the cortical and limbic systems in the central nervous system is reduced. The GABAA receptor is a heteromer composed of five subunits, the most common ones being two αs, two βs, and one γ (α2β2γ). For each subunit, many subtypes exist (α1–6, β1–3, and γ1–3). GABAA receptors containing the α1 subunit mediate the sedative, anterograde amnesic, and partly the anticonvulsive effects of diazepam. GABAA receptors containing α2 mediate the anxiolytic actions and, to a large degree, the myorelaxant effects. GABAA receptors containing α3 and α5 also contribute to benzodiazepines myorelaxant actions, whereas GABAA receptors comprising the α5 subunit were shown to modulate the temporal and spatial memory effects of benzodiazepines. Diazepam is not the only drug to target these GABAA receptors. Drugs such as flumazenil also bind to GABAA to induce their effects.
Sources: en.wikipedia.org
== Efficacy and side effects == Just like cocaine, dimethocaine inhibits the uptake of dopamine in the brain by interfering with the dopamine transporters. The potency of these drugs is linked to their affinity for the dopamine transporters, and their potency to inhibit dopamine uptake. In studies with rhesus monkeys the affinity of dimethocaine for dopamine transporters is smaller than that of cocaine, whereas dimethocaine's potency to inhibit dopamine uptake is similar. This means that more of dimethocaine is needed to reach a similar response. The peak effects occurred within 10 to 20 minutes after the injection and decreased to baseline levels within an hour. Dimethocaine is often abused as a legal substitute for cocaine. The drug is administered intravenously or nasally, because ingestion would lead to rapid hydrolyzation. Its positive effects are euphoria, stimulation, increased talkativeness and mood lift. However, because the drug acts similar as cocaine, it has comparable negative side effects. These side effects include: tachycardia, difficulty with breathing, pain on the chest, vasoconstriction, insomnia, paranoia and anxiety. Dimethocaine probably poses larger health issues than cocaine. This is due to the fact that more dimethocaine must be administered to produce the same euphoric feeling, resulting in larger risk for the negative effects.
5 May The monthly average carbon dioxide (CO2) level in Earth's atmosphere exceeds 420 parts per million (ppm) for the first time in recorded history. A new approach to reverse of neuropathic pain is demonstrated in animals – a gene therapy for local transgenes encoding for (releasing) GABA which is effective for months at a time. A study demonstrates that a 30% caloric restriction extended life spans of male C57BL/6J mice by 10% but when combined with daily intermittent fasting and eating during the most active time of the day it extended life span by 35%.
=== Gambling === To help pay for his 2019 capital spending bill, Pritzker expanded gambling, allowing more casinos and legalized sports betting. This did not mean new casinos could be built and sports betting could begin right away: granting licenses for such activities is the job of the Illinois Gaming Board, and the process is a complex one, lasting several months or more and involving extensive criminal background checks, among other requirements. According to the governor's office, gambling will bring an additional $350 million in revenue each year. This gambling expansion bill extends to Chicago, something the city wanted. Chicago mayor Lori Lightfoot emphasized economic development in the city's South and West sides during her campaign. She has argued that a new casino, privately owned, and associated hospitality and entertainment venues will bring money into the city. On May 5, 2022, Lightfoot announced that she had selected Bally's Corporation's bid to construct a casino resort near the Chicago River.
A Mesmerian Experiment (French: Le Baquet de Mesmer) is a 1905 French silent trick film by Georges Méliès. It was sold by Méliès's Star Film Company and is numbered 693–695 in its catalogues. Méliès appears in the film Doctor Mesmer. The film has few illusions, and is mainly a vehicle for its troupe of dancers, identified in Méliès's American film catalogue as the "Snow-drops" of London's Alhambra Theatre of Variety. The film's technical effects were carried out with pyrotechnics and substitution splices.
Sources: en.wikipedia.org
5-Hydroxytryptophan (5-HTP) can also be administered through a transdermal patch, which was launched in the United Kingdom in early 2014. Rivastigmine, an Alzheimer's treatment medication, was released in patch form in 2007 under the brand name Exelon. In December 2019, Robert S. Langer and his team developed and patented a technique whereby transdermal patches could be used to label people with invisible ink in order to store medical information subcutaneously. This was presented as a boon to "developing nations" where lack of infrastructure means an absence of medical records. The technology uses a "quantum dot dye that is delivered along with a vaccine". Caffeine patches, designed to deliver caffeine to the body through the skin.
*fine chemicals merchant market size, growth potential Examples of applications in eight areas, ranging from adhesives to specialty polymers, are listed in Table 8. Overall, the attractiveness of the fine chemical industry is smaller than the life science industry. The total market, expressed in finished product sales, amounts to $150–200 billion, or about one fourth of the pharma market. The embedded fine chemicals account for an estimated $15 billion. Further disadvantages are the backward integration of the big players, e.g. Akzo-Nobel, Netherlands; Ajinomoto, Japan; Danone, France; Everlight Chemical Industrial Corp., Taiwan; Evonik-Degussa, Germany; Givaudan and Nestlé, Switzerland, Novozymes, Denmark, and Procter & Gamble, and Unilever USA. Innovation is based on new formulations of existing products, rather than the development of new fine chemicals. It is most likely to happen in application areas unrelated to human health, where NCEs are subject to very extensive testing.
It was first detected spectroscopically in late 1931 by Harold Urey, a chemist at Columbia University. Urey's collaborator, Ferdinand Brickwedde, distilled five liters of cryogenically produced liquid hydrogen to 1 mL of liquid, using the low-temperature physics laboratory that had recently been established at the National Bureau of Standards (now National Institute of Standards and Technology) in Washington, DC. The technique had previously been used to isolate heavy isotopes of neon. The cryogenic boiloff technique concentrated the fraction of the mass-2 isotope of hydrogen to a degree that made its spectroscopic identification unambiguous.
Sources: en.wikipedia.org
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.
It normally reports the share of the chromatographic signal that belongs to the main peak, not a measure of activity. A high figure means few related substances were detected under the stated method and wavelength. Different laboratories and methods can return different values for the same material.
Retention time alone is weak evidence, because unrelated peptides can elute at similar positions. Amino acid analysis or peptide mapping gives stronger sequence information when a mass spectrometer is unavailable. Most laboratories still treat mass confirmation as the standard step for verifying the correct compound.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.